Study of Apatinib in Metastatic Esophageal Cancer

Sponsor
Huai'an First People's Hospital
Study ID
NCT02683655
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic Esophageal Cancer.

Key Dates

Start date
Aug 31, 2015
Status verified
Feb 2016
Primary completion
Oct 31, 2016

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib 500mg qd p.o.
    Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
  • Experimental: Apatinib 750mg qd p.o.
    Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy

Primary Outcome Measure

Progression free survival [ Time Frame: An expected average of 12 weeks ]

Central Contacts

  • Chen xiaofei, MD
    +86-13915107001

Related Studies